Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Farmers Insurance
Julphar
Mallinckrodt
Dow
Merck
Cerilliant
Cantor Fitzgerald
Citi

Generated: August 16, 2018

DrugPatentWatch Database Preview

Supernus Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for SUPERNUS PHARMS, and when can generic versions of SUPERNUS PHARMS drugs launch?

SUPERNUS PHARMS has two approved drugs.

There are seventeen US patents protecting SUPERNUS PHARMS drugs. There is one tentative approval on SUPERNUS PHARMS drugs.

There are twenty-five patent family members on SUPERNUS PHARMS drugs in ten countries and one supplementary protection certificate in one country.

Summary for Supernus Pharms
International Patents:25
US Patents:17
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Supernus Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-004 Aug 16, 2013 RX Yes Yes 9,549,940 ➤ Sign Up Y ➤ Sign Up
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-001 Oct 19, 2012 RX Yes No 7,910,131 ➤ Sign Up ➤ Sign Up
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-001 Oct 19, 2012 RX Yes No 8,617,600 ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for SUPERNUS PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Capsules 200 mg ➤ Subscribe 2014-04-03
➤ Subscribe Extended-release Tablets 150 mg and 300 mg ➤ Subscribe 2013-04-12
➤ Subscribe Extended-release Capsules 25 mg, 50 mg, and 100 mg ➤ Subscribe 2014-05-12

Non-Orange Book US Patents for Supernus Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,017,149 Modified release preparations containing oxcarbazepine and derivatives thereof ➤ Sign Up
9,119,792 Modified release preparations containing oxcarbazepine and derivatives thereof ➤ Sign Up
8,211,464 Modified release preparations containing oxcarbazepine and derivatives thereof ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Supernus Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB95/028 United Kingdom ➤ Sign Up PRODUCT NAME: TOPIRAMATE; REGISTERED: UK 0242/0301 19950718
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
AstraZeneca
Harvard Business School
Colorcon
Baxter
Express Scripts
Moodys
Julphar
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.